Rerouting Drug Supplies ‘A Priority’ After Brexit Transition Ends
Industry Again Urged To Stockpile To Mitigate Blockages
Executive Summary
Pharmaceutical companies in the UK have again been asked to ensure they have contingency measures in place to deal with potential supply problems at channel ports – this time in preparation for the UK’s formal departure from the EU’s single market and customs union at the beginning of 2021. The industry is continuing to push for a mutual recognition agreement on drug regulation.
You may also be interested in...
Brexit: Medicine Supplies Face ‘Significant Disruption’ At Ports
As negotiators struggle to reach agreement on the future UK/EU relationship, pharma firms have been warned to expect major hold-ups next year for medicines crossing the Channel.
UK Pharma Exports To Fall 22% In No-Deal Brexit
A new report says that a free trade deal complete with a pharmaceutical mutual recognition agreement is needed to mitigate the damage Brexit will inflict on the global competitiveness of both the UK and the EU.
One Country, Two Regulatory Systems: Another Brexit Headache
The Northern Ireland Protocol brings added complexities that for medicines regulation in the UK, particularly in areas such as new drug approvals and batch release procedures.